556 related articles for article (PubMed ID: 28282497)
1. Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors.
Nafee T; Aslam A; Chi G; Pahlavani S; Nimri D; Kuchkuntla AR; Talib U; Michalak N; Daaboul Y; Korjian S; Gallo A; Gibson CM
Expert Rev Cardiovasc Ther; 2017 Apr; 15(4):237-245. PubMed ID: 28282497
[TBL] [Abstract][Full Text] [Related]
2. Andexanet alfa: a recombinant mimetic of human factor Xa for the reversal of anticoagulant therapies.
Escolar G; Diaz-Ricart M; Arellano-Rodrigo E
Drugs Today (Barc); 2017 May; 53(5):271-282. PubMed ID: 28650000
[TBL] [Abstract][Full Text] [Related]
3. Andexanet alfa for the treatment of hemorrhage.
Cervi A; Crowther M
Expert Rev Hematol; 2018 Nov; 11(11):847-855. PubMed ID: 30296870
[TBL] [Abstract][Full Text] [Related]
4. Andexanet Alfa: First Global Approval.
Heo YA
Drugs; 2018 Jul; 78(10):1049-1055. PubMed ID: 29926311
[TBL] [Abstract][Full Text] [Related]
5. [Andexanet alfa: the best antidote for factor Xa inhibitors?].
Klok FA; Huisman MV
Ned Tijdschr Geneeskd; 2019 Jun; 163():. PubMed ID: 31283119
[TBL] [Abstract][Full Text] [Related]
6. Andexanet alfa for the reversal of factor Xa inhibitors.
Favresse J; Hardy M; van Dievoet MA; Sennesael AL; Douxfils J; Samama CM; Vornicu O; Dincq AS; Lessire S; Mullier F
Expert Opin Biol Ther; 2019 May; 19(5):387-397. PubMed ID: 30974977
[TBL] [Abstract][Full Text] [Related]
7. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
Siegal DM; Curnutte JT; Connolly SJ; Lu G; Conley PB; Wiens BL; Mathur VS; Castillo J; Bronson MD; Leeds JM; Mar FA; Gold A; Crowther MA
N Engl J Med; 2015 Dec; 373(25):2413-24. PubMed ID: 26559317
[TBL] [Abstract][Full Text] [Related]
8. Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants.
Ansell JE
J Thromb Thrombolysis; 2016 Feb; 41(2):248-52. PubMed ID: 26449414
[TBL] [Abstract][Full Text] [Related]
9. Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therapy.
Sartori M; Cosmi B
J Thromb Thrombolysis; 2018 Apr; 45(3):345-352. PubMed ID: 29372400
[TBL] [Abstract][Full Text] [Related]
10. Andexanet Alfa (Andexxa) Formulary Review.
Beik N; Reddy P; Sylvester KW; Connell NT; Giugliano RP; Piazza G; Connors JM
Crit Pathw Cardiol; 2019 Jun; 18(2):66-71. PubMed ID: 31094731
[TBL] [Abstract][Full Text] [Related]
11. A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet Alfa (ANDEXXA).
Rogers KC; Finks SW
Am J Med; 2019 Jan; 132(1):38-41. PubMed ID: 30053385
[TBL] [Abstract][Full Text] [Related]
12. Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence.
Abdulrehman J; Eikelboom JW; Siegal DM
Future Cardiol; 2019 Nov; 15(6):395-404. PubMed ID: 31668083
[TBL] [Abstract][Full Text] [Related]
13. Reversal of direct oral anticoagulants: a practical approach.
Shih AW; Crowther MA
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):612-619. PubMed ID: 27913536
[TBL] [Abstract][Full Text] [Related]
14. Andexanet alfa: A Novel Factor Xa Inhibitor Reversal Agent.
Powell J; Taylor J; Garland SG
Ann Pharmacother; 2019 Sep; 53(9):940-946. PubMed ID: 30813754
[No Abstract] [Full Text] [Related]
15. Throwing it in reverse: An update on reversal of oral factor Xa inhibitors.
Gilbert BW; Reeder JA; Alkhalifah MA; Moran DA; Corvino MA
Am J Emerg Med; 2019 Oct; 37(10):1978-1980. PubMed ID: 30987915
[No Abstract] [Full Text] [Related]
16. Low Risk of Traumatic Intracranial Hematoma Expansion with Factor Xa Inhibitors without Andexanet Reversal.
Maragkos GA; Nelton EB; Richter S; Stippler M
World Neurosurg; 2020 Oct; 142():e95-e100. PubMed ID: 32561488
[TBL] [Abstract][Full Text] [Related]
17. Retrospective review of Andexanet Alfa versus 4-Factor Prothrombin Complex Concentrate for reversal of DOAC-Associated Intracranial Hemorrhage.
Troyer C; Nguyen W; Xie A; Wimer D
J Thromb Thrombolysis; 2023 Jan; 55(1):149-155. PubMed ID: 36355324
[TBL] [Abstract][Full Text] [Related]
18. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.
Milling TJ; Middeldorp S; Xu L; Koch B; Demchuk A; Eikelboom JW; Verhamme P; Cohen AT; Beyer-Westendorf J; Gibson CM; Lopez-Sendon J; Crowther M; Shoamanesh A; Coppens M; Schmidt J; Albaladejo P; Connolly SJ;
Circulation; 2023 Mar; 147(13):1026-1038. PubMed ID: 36802876
[TBL] [Abstract][Full Text] [Related]
19. Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation.
Ghadimi K; Dombrowski KE; Levy JH; Welsby IJ
Expert Rev Hematol; 2016; 9(2):115-22. PubMed ID: 26686866
[TBL] [Abstract][Full Text] [Related]
20. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
Tummala R; Kavtaradze A; Gupta A; Ghosh RK
Int J Cardiol; 2016 Jul; 214():292-8. PubMed ID: 27082776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
